An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Requirement
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
BeyondSpring Inc. has regained compliance with the minimum bid price requirement set forth by Nasdaq. The closing bid price of the company's ordinary shares has been at $1.00 per share or greater for 10 consecutive business days.
Positive
None.
Negative
None.
NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced that on October 27, 2023, it received a written notification (the “Notification Letter on Compliance”) from the Listing Qualifications Department from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules.
According to the Notification Letter on Compliance, the staff of Nasdaq has determined that for the 10 consecutive business days, from October 13, 2023 to October 26, 2023, the closing bid price of the Company’s ordinary shares has been at $1.00 per share or greater, and the Company has regained compliance with the Nasdaq Listing Rule 5550(a)(2) and the bid price deficiency matter as previously disclosed is now closed.
About BeyondSpring BeyondSpring (NASDAQ: BYSI) is a global clinical-stage biopharmaceutical company focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company is advancing its first-in-class lead asset, Plinabulin, as a direct anti-cancer agent in various cancer indications and to prevent chemotherapy-induced neutropenia. Its pipeline also includes three preclinical immuno-oncology assets. Additionally, BeyondSpring’s subsidiary, SEED Therapeutics, leverages a proprietary targeted protein degradation (TPD) drug discovery platform and has an initial R&D collaboration with Eli Lilly. Learn more by visiting https://beyondspringpharma.com.
What is the company that issued the press release?
The company that issued the press release is BeyondSpring Inc.
What is the stock ticker symbol of BeyondSpring Inc.?
The stock ticker symbol of BeyondSpring Inc. is BYSI.
What is the focus of BeyondSpring Inc.?
BeyondSpring Inc. is a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs.
What compliance did BeyondSpring Inc. regain?
BeyondSpring Inc. regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules.
What was the closing bid price of BeyondSpring Inc.'s ordinary shares?
The closing bid price of BeyondSpring Inc.'s ordinary shares has been at $1.00 per share or greater for 10 consecutive business days.
beyondspring pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies. we are currently advancing the development of our lead asset plinabulin, a novel cancer therapeutic, in a global phase 3 trial in non-small-cell lung cancer (nsclc) and initiating a pivotal global phase 3 trial in prevention of docetaxel-induced neutropenia. as a tubulin depolymerizing agent, plinabulin works via multiple mechanisms of action to target and alter the tumor microenvironment: 1. immune enhancing effects via dendritic cell maturation 2. tumor cell apoptosis via activation of ras-jnk pathway 3. vascular disruptive effects given plinabulin’s potential as a tumor micro-environment targeting agent, we intend to initiate clinical trials in additional cancer indications: • immuno-oncology, with immune checkpoint inhibitors in nsclc • cns malignancies including glioblastoma (gbm) • kras positive mutant cancers
